Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 6/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.54 |
| ▸ | NPY1R | P25929 | 3/20 | 0.53 |
| ▸ | NPY2R | P49146 | 3/20 | 0.53 |
| ▸ | NPY4R | P50391 | 3/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.52 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.52 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.51 |
| ▸ | GLP1R | P43220 | 1/20 | 0.51 |
| ▸ | GCGR | P47871 | 1/20 | 0.51 |
| ▸ | GIPR | P48546 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29534023 | 1.00 | GHSR (0.55) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL3486221 | 0.94 | GHSR (0.61) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL30466124 | 0.94 | GHSR (0.61) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL3486226 | 0.94 | GHSR (0.61) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL29434320 | 0.94 | GHSR (0.61) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL19731345 | 0.92 | KISS1R (0.54) | GHSRKISS1RNPY1RNPY2RNPY4R | |
| SCHEMBL24172454 | 0.90 | IL23R (0.61) | GHSRKISS1RNPY2RIL23RGLP1R | |
| SCHEMBL19731216 | 0.90 | IL23R (0.61) | GHSRKISS1RNPY2RIL23RGLP1R | |
| SCHEMBL16692892 | 0.90 | IL23R (0.61) | GHSRKISS1RNPY2RIL23RGLP1R | |
| SCHEMBL19731206 | 0.90 | IL23R (0.61) | GHSRKISS1RNPY2RIL23RGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12364755-B2 | Method for obtaining globally activated monocytes | TRANSIMMUNE AG (DE) | 2025-07-22 | — | — | US | disclosed |
| US-20250032573-A1 | IMMUNITY-ENHANCING PEPTIDE ANALOGS AND USES THEREOF | Research & Business Foundation Sungkyunkwan University (KR) | 2025-01-30 | — | — | US | disclosed |
| CN-119258284-A | Nano needle and preparation method and application thereof | 国家纳米科学中心 | 2025-01-07 | — | — | CN | disclosed |
| EP-3741843-B1 | METHOD FOR OBTAINING IMMUNO-STIMULATORY DENDRITIC CELLS | TRANSIMMUNE AG (DE) | 2024-06-26 | — | — | EP | disclosed |
| US-20240173375-A1 | CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO | BIOTEMPT B.V. (NL) | 2024-05-30 | — | — | US | disclosed |
| EP-4301391-A1 | CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO | Biotempt B.V. (NL) | 2024-01-10 | — | — | EP | disclosed |
| US-20230414764-A1 | Template Assembly by Proximity-Enhanced Reactivity via Metabolic Labeling | MASSACHUSETTS GEN HOSPITAL (US) | 2023-12-28 | — | — | US | disclosed |
| EP-3954377-B1 | METHOD FOR OBTAINING GLOBALLY ACTIVATED MONOCYTES | TRANSIMMUNE AG (DE) | 2023-09-06 | — | — | EP | disclosed |
| WO-2022186690-A1 | CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO. | BIOTEMPT B.V. (NL) | 2022-09-09 | — | — | WO | disclosed |
| US-20220280562-A1 | METHOD FOR OBTAINING GLOBALLY ACTIVATED MONOCYTES | TRANSIMMUNE AG (DE) | 2022-09-08 | — | — | US | disclosed |
| US-20220259556-A1 | METHOD FOR OBTAINING IMMUNO-SUPPRESSIVE DENDRITIC CELLS | TRANSIMMUNE AG (DE) | 2022-08-18 | — | — | US | disclosed |
| WO-2022099055-A1 | TEMPLATE ASSEMBLY BY PROXIMITY-ENHANCED REACTIVITY VIA METABOLIC LABELING | THE GENERAL HOSPITAL CORPORATION (US) | 2022-05-12 | — | — | WO | disclosed |
| CN-114410581-A | Method for obtaining immunosuppressive dendritic cells | 特兰西穆内有限公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-106604988-B | Method for obtaining globally activated monocytes | 特兰西穆内有限公司 | 2022-04-19 | — | — | CN | disclosed |
| US-20220112462-A1 | METHOD FOR OBTAINING IMMUNO-STIMULATORY DENDRITIC CELLS | TRANSIMMUNE AG (DE) | 2022-04-14 | — | — | US | disclosed |
| US-20220106597-A1 | Methods For Preventing Titration Of Bimolecular Templated Assembly Reactions By Structurally-Determined Differential Hybridizations | TRIBIOTICA LLC | 2022-04-07 | — | — | US | disclosed |
| EP-3954377-A1 | METHOD FOR OBTAINING GLOBALLY ACTIVATED MONOCYTES | Transimmune AG (DE) | 2022-02-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250032573-A1 | IMMUNITY-ENHANCING PEPTIDE ANALOGS AND USES THEREOF | FPR3, FPR1, FPR2 | GHSR 1228/4885KISS1R 1494/4885NPY1R 109/4885 |
| US-20230414764-A1 | Template Assembly by Proximity-Enhanced Reactivity via Metabolic Labeling | MLYCD, COASY, HOGA1 | GHSR 4407/4885KISS1R 3523/4885NPY1R 3694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.